Predictive Value of Tertiary Lymphoid Structures Assessed by High Endothelial Venule Counts in the Neoadjuvant Setting of Triple-Negative Breast Cancer

In Hye Song; Sun-Hee Heo; Won Seon Bang; Hye Seon Park; In Ah Park; Young-Ae Kim; Suk Young Park; Jin Roh; Gyungyub Gong; Hee Jin Lee

doi:10.4143/crt.2016.215

Articles

Page Path: HOME > Cancer Res Treat > Volume 49(2); 2017 > Article

Original Article Predictive Value of Tertiary Lymphoid Structures Assessed by High Endothelial Venule Counts in the Neoadjuvant Setting of Triple-Negative Breast Cancer: In Hye Song, MD¹, Sun-Hee Heo, PhD^1,2, Won Seon Bang, BS¹, Hye Seon Park, BS¹, In Ah Park, MD¹, Young-Ae Kim, PhD^1,2, Suk Young Park, MS¹, Jin Roh, MD¹, Gyungyub Gong, MD, PhD¹, Hee Jin Lee, MD, PhD^1,; Cancer Research and Treatment : Official Journal of Korean Cancer Association 2017;49(2):399-407.
DOI: https://doi.org/10.4143/crt.2016.215
Published online: July 27, 2016

¹Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea

²Asan Institute for Life Sciences, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea

Correspondence: Hee Jin Lee, MD, PhD Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-ro-43-gil, Songpa-gu, Seoul 05505, Korea
Tel:82-2-3010-5889 Fax:82-2-472-7898 E-mail: backlila@gmail.com

*In Hye Song and Sun-Hee Heo contributed equally to this work.

• Received: May 24, 2016 • Accepted: June 30, 2016

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

15,844 Views
569 Download
104 Web of Science
98 Crossref
104 Scopus

prev next

Full Article

Download PDF

Abstract

Purpose
The tertiary lymphoid structure (TLS) is an important source of tumor-infiltrating lymphocytes (TILs), which have a strong prognostic and predictive value in triple-negative breast cancer (TNBC). A previous study reported that the levels of CXCL13 mRNA expression were associated with TLSs, but measuring the gene expression is challenging in routine practice. Therefore, this study evaluated the MECA79-positive high endothelial venule (HEV) densities and their association with the histopathologically assessed TLSs in biopsy samples. In addition, the relationship of TLSs with the CXCL13 transcript levels and clinical outcomes were examined.
Materials and Methods
A total of 108 TNBC patients treated with neoadjuvant chemotherapy (NAC) were studied. The amounts of TILs and TLSs were measured histopathologically using hematoxylin and eosin–stained slides. The HEV densities and TIL subpopulations were measured by immunohistochemistry for MECA79, CD3, CD8, and CD20. CXCL13mRNA expression levels using a NanoString assay (NanoString Technologies).
Results
The mean number of HEVs in pre-NAC biopsies was 12 (range, 0 to 72). The amounts of TILs and TLSs, HEV density, and CXCL13 expression showed robust correlations with each other. A lower pre-NAC clinical T stage, higher TIL and TLS levels, a higher HEV density, CD20-positive cell density, and CXCL13 expression were significant predictors of a pathologic complete response (pCR). Higher CD8-positive cell density and levels of CXCL13 expression were significantly associated with a better disease-free survival rate.
Conclusion
MECA79-positive HEV density in pre-NAC biopsies is an objective and quantitative surrogate marker of TLS and might be a valuable tool for predicting pCR of TNBC in routine pathology practice.
Key words: Triple-negative breast neoplasms, Immunohistochemistry, Tertiary lymphoid structure, Prognosis

Introduction

Recently, tumor-infiltrating lymphocytes (TILs) have been strongly associated with the anti-tumor immunity and have shown prognostic and predictive significance in a range of types of solid neoplasms [1-4]. Triple-negative breast cancers (TNBCs) show the poorest prognosis among all breast cancer subtypes; there are no known targeted treatments for this subgroup of patients. On the other hand, previous studies have indicated that a large number of TILs are associated with high response rates to neoadjuvant chemotherapy (NAC) along with good survival rates in patients with TNBC [5]. Moreover, accumulating evidence suggests that immunotherapy might have great potential for treating TNBCs [6]. Therefore, gaining a better understanding of the mechanism whereby lymphoid cells infiltrate tumors and interact with malignant cells might facilitate the development of more efficient immunotherapy.

Tertiary lymphoid structures (TLSs) are one of the major sources of TILs. TLSs are ectopic, vascularized lymphoid formations that can be found in inflamed or tumoral tissues [7]. In breast cancers, TLSs can be observed mainly in areas that surround the tumor and adjacent normal terminal ductal lobular units [8]. The mechanism whereby TLSs are formed is not known, but the roles for high endothelial venules (HEVs) and the chemokine CXCL13 have been suggested [9]. The HEVs are specialized blood vessels with plump and cuboidal endothelial cells, which express the peripheral node addressin (PNAd) and facilitate the extravasation of lymphocytes from the bloodstream and formation of TLSs [10]. Many studies have reported positive correlations between the TLS components, particularly HEV, and favorable clinical outcomes in various types of cancer, such as cutaneous melanoma, non-small cell lung cancer, colorectal carcinoma, and breast carcinoma [7,11-13]. Gu-Trantien et al. [14] reported that the infiltration of CXCL13-producing CD4⁺ follicular helper T cells and a CXCL13 gene expression signature are related to a longer disease-free survival in breast cancer patients. A previous study recently suggested that increased CXCL13 gene expression is predictive of a more frequent pathologic complete response (pCR) and a good prognosis in TNBC patients treated with NAC [15].

Despite the clinical significance of TLSs and TILs, they are difficult to assess in situ. The term TLS can only be used when the structure exhibits all of the following features: distinct and adjacent T and B cell compartments, fibroblastic reticular cells, HEVs, activation-induced cytidine deaminase enzyme expression, and follicular dendritic cells [16]. On the other hand, in clinical practice, it can be difficult to distinguish simple lymphoid aggregations from true TLSs using histopathological assessments alone. MECA79, which is an epitope binding to CD62L and induces TLS formation, can be used to evaluate TLS, but there has been no trial using MECA79 in tumor tissues [10]. In addition, measurements of TILs do not allow for the differentiation of various subpopulations, and there has been no consistent evidence regarding which TIL subpopulation(s) play the dominant role in anti-tumor immunity and are associated with good clinical outcomes. Some papers have reported that the presence of CD8-positive cytotoxic T cells is the most important predictive and prognostic factor in breast cancer [17,18], whereas others have underscored the significance of B cells [19,20].

Therefore, this study evaluated the amount of TLSs in preNAC core needle biopsies of TNBC by calculating the MECA79-positive HEV density, measuring the TIL subpopulations by immunohistochemistry (IHC), and using a digital computer analyzer, and assessed their relationship with CXCL13 mRNA expression and the clinical outcomes.

Materials and Methods

1. Patients

A total of 108 patients, who were diagnosed with primary TNBC, received anthracycline and taxane-based NAC, and were treated surgically between 2010 and 2012 at the Asan Medical Center, were enrolled in this study. All patients received anthracycline and taxane-based regimens, which included four cycles of 60 mg/m² adriamycin and 600 mg/m² cyclophosphamide followed by four cycles of 75 mg/m² docetaxel. Surgery was performed ~3-4 weeks after the last chemotherapy cycle. The occurrence of pCR was defined as the absence of a residual invasive carcinoma in the breast and regional lymph nodes (ypT0/Tis, N0). Approval of the study protocol was granted by the Institutional Review Board of the Asan Medical Center (approval number: 2013-0866).

The patients’ medical records were reviewed to gather clinical information. The histological parameters were evaluated based on hematoxylin and eosin (H&E)–stained slides and pathology reports. The clinicopathological parameters evaluated in each case included the patients’ age at diagnosis, sex, tumor size, histological subtype, histological grade, pathologic tumor (pT) stage, lymphovascular invasion, lymph node metastasis, overall tumor stage, the presence or absence of recurrence, the most recent follow-up date, and the survival status.

2. Histological evaluations

The entire tumor bed was submitted for a pathological evaluation. H&E-stained slides of the pre-NAC biopsy and post-NAC surgery samples of all 108 tumors were reviewed for a histological diagnosis, subtype and grade, tumor size, ypT stage, ypN stage, lymphovascular invasion, and responsiveness to chemotherapy. The histological type was defined based on the 2012 World Health Organization classification criteria, and the histological grade was assessed using the modified Bloom-Richardson classification. The Miller-Payne grade and residual cancer burden (RCB) were also assessed for their response to chemotherapy [21]. Pre-NAC biopsy slides were analyzed histopathologically to determine the level of TILs (this is defined as the mean percentage of stroma of an invasive carcinoma infiltrated by lymphocytes and plasma cells in 10% increments; 1% or 5% criteria were used if less than 10% of stroma was infiltrated by TILs; all available full sections were evaluated) [22], the TLSs in the adjacent tissues, including carcinoma in situ components (none, little, moderate, or abundant), and the presence or absence of a germinal center in TLSs. Lymphoid aggregation with vessels that exhibited HEV-like features (plump, cuboidal endothelial cells) with or without germinal centers was considered to be a TLS.

3. Immunohistochemical evaluations

Among the 108 cases, formalin-fixed paraffin-embedded (FFPE) tissue samples were available for 55 cases, which were analyzed by IHC and mRNA expression. The FFPE tissue sections were stained using an automatic immunohistochemical staining device (Benchmark XT, Ventana Medical Systems, Tucson, AZ). The antibodies to CD3 (1:50, Novocastra Laboratories, Newcastle upon Tyne, UK), CD8 (1:400, Dako, Glostrup, Denmark), CD20 (1:500, Novocastra Laboratories), and MECA79 (1:200, Santa Cruz Biotechnology, Dallas, TX; recognizes sulfate-dependent carbohydrate epitopes of PNAd expressed in endothelial cells of HEVs), were used. The total number of MECA79-positive blood vessels in each slide were counted manually.

The immunostained slides were scanned using a digital microscopy scanner (Pannoramic 250 FLASH, 3DHISTECH Ltd., Budapest, Hungary). The entire tumor area was selected in whole slides. In each case, the images were then scanned using computer viewer software (Pannoramic Viewer 1.15.2, 3DHISTECH Ltd.) and the number of CD3-, CD8-, and CD20-positive lymphocytes were counted in the tumor area using the NuclearQuant module. The positive cell densities were calculated by dividing the immuno-positive cell numbers by the tumor area.

4. Gene expression analysis using a NanoString nCounter system

The levels of the CXCL13 mRNA transcripts in the FFPE tissue samples were evaluated by digital transcript counting (nCounter GX Human Immunology V2 Kit) assay (NanoString Technologies, Seattle, WA) [23]. The total RNA (100 ng) was assayed on a Counter Digital Analyzer (NanoString Technologies) according to the manufacturer’s instructions. The data were normalized by scaling with the geometric mean of the built-in control gene probes for each sample. Finally, a log transformation (base 2) was performed.

5. Statistical analysis

All statistical analyses were performed using the SPSS ver. 18 (SPSS Inc., Chicago, IL). Wilcoxon signed-rank tests, Kruskal-Wallis tests, Mann-Whitney U tests, Fisher exact tests, logistic regression, Spearman’s correlations, and binary logistic regression were used where appropriate. A threshold for statistical significance was set to 5%.

Results

1. Clinicopathological characteristics of the study cases

The patients’ ages ranged from 23 to 70 years (median, 42 years); all patients were women. Among the 108 cases analyzed, eight were cT1 tumors, 58 were cT2 tumors, 37 were cT3 tumors, and five were cT4 tumors. For the nodal status, there were six cN0 tumors, 48 cN1 tumors, 23 cN2 tumors, and 31 cN3 tumors. For staging, 37 and 71 were clinical stage II and III, respectively. pCR was achieved in 33 of 108 tumors (30.6%). The median patient follow-up duration was 34.9 months (range, 12.0 to 55.8 months). The mean TIL level was 24.6±20.8 (%). Table 1 summarizes the clinicopathological characteristics of the tumors without and with available FFPE blocks. No significant differences were observed between the two groups regarding the patients’ age, clinical T or N stage, histological grade, TILs, TLSs, pCR rate, Miller-Payne grade, or RCB class.

2. Predictive value and prognostic significance of TILs and TLSs

Based on assessments of the H&E-stained sections, uniand multi-variate analyses were performed to assess the associations between pCR, TIL, and other established clinicopathological parameters (Table 2). Among the 108 tumors, univariate logistic regression analysis revealed a lower cT stage and higher TIL and TLS levels in the pre-NAC biopsy to be significantly associated with pCR. Multivariate analysis, including the cT stage, TIL, and TLS, showed that only TIL (hazard ratio [HR], 1.038; 95% confidence interval [CI], 1.012 to 1.065; p=0.004) was an independent predictor of pCR. In univariate disease-free survival analysis, the cT and TIL were closely associated with a longer disease-free survival rate (Table 3). On the other hand, the TLS level was not significantly associated with the patients’ survival. Multivariate analysis, including the cT stage, cN stage, TIL, and TLS, showed that only TIL (HR, 0.975; 95% CI, 0.954 to 0.997; p=0.028) was a robust independent prognostic factor for the disease-free survival.

3. Correlations of various parameters associated with TILs

IHC and gene expression analyses were carried out in 55 cases with available FFPE tissue blocks. The median of the tissue areas in each slide was 69.46 mm² (range, 23.47 to 175.33 mm²), whereas the median of the tumor areas was 20.92 mm² (range, 1.23 to 83.15 mm²). The total number of HEVs in each slide ranged from 0 to 72. Most of the HEVs were located in the peritumoral areas. The mean MECA79-positive HEV density in each slide was 0.169±0.223/mm² (Fig. 1). Finally, the mean CD3-, CD8-, and CD20-positive cell densities in the tumor areas of each slide were 357.2±412.2/mm², 402.2±382.4/mm², and 246.8±343.5/mm², respectively (Fig. 2). The TIL and TLS levels were correlated based on the H&E-stained slides, the densities of HEV and TIL subpopulations, and expression levels of the CXCL13 mRNA transcripts using the NanoString method with the pathological responses to NAC (Supplementary Table 1). The TLS levels were correlated significantly with the TIL levels, CD3-, CD8-, and CD20-positive cell densities, the HEV density, and expression levels of the CXCL13 mRNA transcripts. The Miller-Payne grade was significantly correlated with the TLS level, CD20-positive cell density, HEV density, and expression levels of CXCL13 mRNA transcripts. Finally, the RCB class was correlated significantly with CXCL13 expression.

4. Predictive value and prognostic significance of the TIL subpopulations and HEV densities evaluated by IHC

Based on an analysis of the IHC slides, 17 patients (30.1%) with available FFPE tissue blocks achieved pCR; none of these patients showed a recurrence during a median follow-up period of 31.4 months (range, 21.1 to 53.0 months). Among the patients without pCR (n=38), approximately half had disease recurrence (range of recurrence-free survival, 1.5 to 19.7 months). CD20-positive cell density (HR, 1.004; 95% CI, 1.000 to 1.007; p=0.037), HEV density (HR, 20.325; 95% CI, 1.455 to 283.857; p=0.025), and the levels of the CXCL13 mRNA transcripts (HR, 1.706; 95% CI, 1.079 to 2.696; p=0.022) were correlated significantly with pCR. In survival analysis, the CD8-positive cell density and levels of the CXCL13 mRNA transcripts were closely associated with the disease-free survival (Table 4).

Discussion

To the best of the authors’ knowledge, the current study is the first to identify and measure the TLSs in biopsy specimens in an NAC setting, and evaluate their predictive value. Several reports have indicated a prognostic value for the presence of TLSs in cancers [7,11-14]. On the other hand, no studies have assessed this in the context of NAC, which is performed frequently in the treatment of breast cancer. In the present study, both higher levels of TLSs represented by MECA79-positive HEV densities and higher levels of TILs in the H&E slides were found to be predictors of pCR.

In previous studies, the optimal way to measure the TLSs is controversial. Currently, measurements of TILs are generally performed based on visual assessments of the H&E-stained sections, which is an inexpensive, simple, and versatile method that is often easier to perform than complementary methods, such as IHC [22]. In H&E-stained tissues, however, it can be difficult to distinguish lymphoid aggregates from true TLSs and it is particularly challenging to quantify the amount of TLSs. In addition, there have been trials in which dendritic cell–lysosomal associated membrane protein (DC-LAMP)–positive dendritic cells were counted as surrogate markers for TLSs [11]. This represents a quantitative and objective method compared to simple visual assessments, even though counting a large number of small dendritic cells by microscopy is quite demanding. In addition, the TLSs show a wide spatial heterogeneity in tumor tissues, and may therefore, be underrepresented when measured in small core needle biopsy specimens or with tissue microarrays [22]. This can be problematic for breast cancers because many breast cancer patients only receive neoadjuvant systemic therapy after a needle biopsy, which represents the only tissue reference available for determining the drug regimens and assessing responses. Previously, the expression of immune-related genes in pre-NAC biopsies obtained from TNBC patients was investigated and the expression of the CXCL13 mRNA transcripts, which encodes a potent B cell-attracting chemokine that contributes to TLS formation in inflammatory and cancerous settings, was found to be a predictor of pCR, which indicates a better prognosis in TNBC patients [15]. On the other hand, it can be easy to under or overestimate gene expression analyses of each biopsy specimen because the proportion of tumor versus normal tissues in a biopsy specimen is not considered. Furthermore, gene expression analysis is expensive and can be cumbersome to perform in daily pathology practice.

Despite these difficulties, the present study obtained some important findings based on MECA79 IHC staining. The number of MECA79-positive HEVs were counted in each slide and the HEV density was calculated. This quantitative method is easier than counting DC-LAMP because of the small number of HEVs. The HEV density was positively correlated with the amount of TLSs measured by assessing the H&E slides, and a greater HEV density was not only a predictor of pCR, but was also associated with a better disease-free survival. HEVs contribute to TIL infiltration, and consequently to anti-tumor immunity, so cancer immuntherapy approaches have been proposed, in which the endothelial cell properties are modified to increase immune cell infiltration [24]. Hopefully, the discovery of a method to increase HEV in the peritumoral areas will be beneficial for the development of treatment strategies for breast cancer, along with many other cancer types.

Finally, the densities of the TIL subpopulations were measured based on IHC staining for CD3, CD8, and CD20, along with a digital microscopic scanner and automated analysis software. Several studies used IHC to evaluate the TIL subpopulations in breast cancer [7,20,25-27]. On the other hand, most of those studies used semiquantitative methods for the measurements because fully quantitative methods are often difficult and time-consuming due to the large number of TILs. Using automated computer software, quantified the cell densities were more accurately and the inter-observer bias was avoided. A higher CD20-positive cell density was found to be a predictor of pCR, whereas a higher CD8-positive cell density was associated with a better disease-free survival. CD8-positive cytotoxic T lymphocytes exhibit antitumor effects via direct tumor cell lysis and interferon γ release, which are strongly associated with better therapeutic responses and enhanced patient survival [17,26]. In contrast, the effects of B cells on the tumors remain the subject of debate. Some studies have reported that B-cell infiltration is associated with a good prognosis [20,25]. The possible mechanisms whereby B cells might mediate improved anti-tumor responses have been suggested, such as the generation of anti-tumor antibodies, the secretion of proimmunogenic cytokines and chemokines, antigen presentation to T cells, and direct cytotoxicity via granzyme B production [28]. Nevertheless, more study will be needed to explore how the immune components interact in response to tumors.

Conclusion

The density of MECA79-positive HEV is an easy to assess and accurate surrogate marker of TLS in needle biopsies of TNBC. Moreover, it is positively correlated with pCR in the context of NAC. Overall, approaches to increase HEV may be beneficial in cancer immunotherapy.

Electronic Supplementary Material

Supplementary materials are available at Cancer Research and Treatment website (http://www.e-crt.org).

crt-2016-215-supple.pdf

NOTES

Conflict of interest relevant to this article was not reported.

Acknowledgements

This study was supported by the Basic Science Research Program administered by the National Research Foundation of Korea (NRF) and funded by the Ministry of Science, ICT & Future Planning (2015R1C1A1A02036484). Gyungyub Gong works as a consultant for Genentech.

Fig. 1.

High endothelial venules (HEVs) in needle biopsy specimens of triple-negative breast cancer. (A) Representative microscopic images of HEVs immunohistochemically stained with MECA79 (×400). (B) Absolute number and density of HEVs in tumors (n=55).

Fig. 2.

Representative microscopy images of tumor-infiltrating lymphocyte subpopulations in triple-negative breast cancer sections with immunohistochemical staining.

Table 1.

Clinicopathologic characteristics of the tumors according to the availability of FFPE tumor blocks

Parameter	Tumors without available FFPE blocks (n=53)	Tumors with available FFPE blocks (n=55)	p-value
Age (yr)	43.9±10.2	41.4±9.6	0.181
Clinical tumor stage
T1	4 (7.5)	4 (7.3)	0.942
T2	27 (50.9)	31 (56.4)
T3	19 (35.8)	18 (32.7)
T4	3 (5.7)	2 (3.6)
Clinical nodal status
N0	5 (9.4)	1 (1.8)	0.331
N1	21 (39.6)	27 (49.1)
N2	12 (22.6)	11 (20.0)
N3	15 (28.3)	16 (29.1)
Histologic grade
2	24 (45.3)	25 (45.5)	1
3	29 (54.7)	30 (54.5)
TIL (%)	23.3±20.6	25.9±21.0	0.471
TLS
None	9 (22.5)	6 (13.0)	0.198
Mild	12 (30.0)	9 (19.6)
Moderate	14 (35.0)	18 (39.1)
Abundant	5 (12.5)	13 (28.3)
Germinal center in TLSs
Absent	36 (97.3)	44 (95.7)	1
Present	1 (2.7)	2 (4.3)
pCR
Absent	37 (69.8)	38 (69.1)	1
Present	16 (30.2)	17 (30.9)
Miller-Payne grade
Grade 1	1 (1.9)	0	0.115
Grade 2	2 (3.8)	10 (18.2)
Grade 3	18 (34.0)	14 (25.5)
Grade 4	12 (22.6)	13 (23.6)
Grade 5	20 (37.7)	18 (32.7)
RCB class
0	16 (30.2)	17 (30.9)	0.295
1	5 (9.4)	1 (1.8)
2	20 (37.7)	27 (49.1)
3	12 (22.6)	10 (18.2)

Values are presented as mean±standard deviation or number (%). FFPE, formalin-fixed paraffin-embedded; TIL, tumor-infiltrating lymphocytes; TLS, tertiary lymphoid structure; pCR, pathologic complete response; RCB, residual cancer burden.

Table 2.

Predictive values of TIL, TLS, and other clinicopathological parameters prior to neoadjuvant chemotherapy for a pathologic complete response in 108 cases

Parameter	Univariate analysis			Multivariate analysis
Parameter	HR	95% CI	p-value	HR	95% CI	p-value
Clinical tumor stage			0.067			0.304
T1
T2	0.150	0.028-0.816	0.028	0.294	0.046-1.862	0.193
T3	0.092	0.015-0.546	0.009	0.147	0.020-1.094	0.061
T4	0.083	0.006-1.257	0.073	0.289	0.015-5.418	0.406
Clinical nodal status			0.690			-
N0
N1	1.097	0.182-6.618	0.920	-	-	-
N2	0.875	0.129-5.943	0.891	-	-	-
N3	0.583	0.088-3.880	0.577	-	-	-
Histologic grade (3 vs. 2)	1.704	0.735-3.953	0.214	-	-	-
TIL in biopsies	1.025	1.005-1.046	0.016	1.038	1.012-1.065	0.004
TLS in biopsies			0.147			0.925
None
Little	2.031	0.337-12.24	0.439	1.086	0.158-7.472	0.933
Moderate	2.955	0.559-15.63	0.202	1.478	0.248-8.815	0.668
Abundant	6.500	1.127-37.48	0.036	1.721	0.213-13.92	0.611

TIL, tumor-infiltrating lymphocytes; TLS, tertiary lymphoid structure; HR, hazard ratio; CI, confidence interval.

Table 3.

Disease-free survival analyses based on TIL, TLS, and clinicopathological parameters in 108 cases

Parameter	Univariate analysis			Multivariate analysis
Parameter	HR	95% CI	p-value	HR	95% CI	p-value
cT stage (T3-4 vs. T1-2)	2.335	1.252-4.355	0.008	1.877	0.923-3.813	0.082
cN stage (N2-3 vs. N0-1)	1.652	0.881-3.096	0.117	1.722	0.847-3.501	0.133
Histologic grade (3 vs. 2)	0.796	0.427-1.483	0.473
TIL in biopsies	0.975	0.957-0.993	0.007	0.975	0.954-0.997	0.028
TLS in biopsies (abundant vs. none to moderate)	0.327	0.100-1.074	0.065	0.624	0.164-2.374	0.489

TIL, tumor-infiltrating lymphocytes; TLS, tertiary lymphoid structure; HR, hazard ratio; CI, confidence interval.

Table 4.

Predictive value for pCR and the prognostic significance of the protein and gene expression of TIL-associated molecules and HEV density in cases with available FFPE tissue blocks

Parameter	Predictive value for pCR			Disease-free survival
Parameter	HR	95% CI	p-value	HR	95% CI	p-value
HEV density	20.325	1.455-283.857	0.025	0.091	0.006-1.421	0.087
CD8-positive cell density	1.001	0.999-1.002	0.222	0.998	0.996-1.000	0.037
CD3-positive cell density	1.003	1.000-1.005	0.052	0.999	0.997-1.001	0.452
CD20-positive cell density	1.004	1.000-1.007	0.037	0.998	0.996-1.001	0.194
CXCL13 gene expression	1.706	1.079-2.696	0.022	0.634	0.478-0.841	0.002

pCR, pathologic complete response; TIL, tumor-infiltrating lymphocyte; HEV, high endothelial venule; FFPE, formalin-fixed paraffin-embedded; HR, hazard ratio; CI, confidence interval.

REFERENCES

1. Aaltomaa S, Lipponen P, Eskelinen M, Kosma VM, Marin S, Alhava E, et al. Lymphocyte infiltrates as a prognostic variable in female breast cancer. Eur J Cancer. 1992;28A:859–64. Article PubMed
2. Clemente CG, Mihm MC Jr, Bufalino R, Zurrida S, Collini P, Cascinelli N. Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer. 1996;77:1303–10. Article PubMed
3. Lee HJ, Seo JY, Ahn JH, Ahn SH, Gong G. Tumor-associated lymphocytes predict response to neoadjuvant chemotherapy in breast cancer patients. J Breast Cancer. 2013;16:32–9. Article PubMed PMC
4. Ahn SG, Jeong J, Hong S, Jung WH. Current Issues and clinical evidence in tumor-infiltrating lymphocytes in breast cancer. J Pathol Transl Med. 2015;49:355–63. Article PubMed PMC PDF
5. West NR, Milne K, Truong PT, Macpherson N, Nelson BH, Watson PH. Tumor-infiltrating lymphocytes predict response to anthracycline-based chemotherapy in estrogen receptor-negative breast cancer. Breast Cancer Res. 2011;13:R126.Article PubMed PMC
6. Stagg J, Allard B. Immunotherapeutic approaches in triple-negative breast cancer: latest research and clinical prospects. Ther Adv Med Oncol. 2013;5:169–81. Article PubMed PMC
7. Martinet L, Garrido I, Filleron T, Le Guellec S, Bellard E, Fournie JJ, et al. Human solid tumors contain high endothelial venules: association with T- and B-lymphocyte infiltration and favorable prognosis in breast cancer. Cancer Res. 2011;71:5678–87. Article PubMed
8. Lee HJ, Kim JY, Park IA, Song IH, Yu JH, Ahn JH, et al. Prognostic significance of tumor-infiltrating lymphocytes and the tertiary lymphoid structures in HER2-positive breast cancer treated with adjuvant trastuzumab. Am J Clin Pathol. 2015;144:278–88. Article PubMed
9. Martinet L, Le Guellec S, Filleron T, Lamant L, Meyer N, Rochaix P, et al. High endothelial venules (HEVs) in human melanoma lesions: major gateways for tumor-infiltrating lymphocytes. Oncoimmunology. 2012;1:829–39. Article PubMed PMC
10. Girard JP, Moussion C, Forster R. HEVs, lymphatics and homeostatic immune cell trafficking in lymph nodes. Nat Rev Immunol. 2012;12:762–73. Article PubMed
11. Ladanyi A, Kiss J, Somlai B, Gilde K, Fejos Z, Mohos A, et al. Density of DC-LAMP(+) mature dendritic cells in combination with activated T lymphocytes infiltrating primary cutaneous melanoma is a strong independent prognostic factor. Cancer Immunol Immunother. 2007;56:1459–69. Article PubMed PMC
12. Dieu-Nosjean MC, Antoine M, Danel C, Heudes D, Wislez M, Poulot V, et al. Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures. J Clin Oncol. 2008;26:4410–7. Article PubMed
13. Di Caro G, Bergomas F, Grizzi F, Doni A, Bianchi P, Malesci A, et al. Occurrence of tertiary lymphoid tissue is associated with T-cell infiltration and predicts better prognosis in early-stage colorectal cancers. Clin Cancer Res. 2014;20:2147–58. Article PubMed
14. Gu-Trantien C, Loi S, Garaud S, Equeter C, Libin M, de Wind A, et al. CD4(+) follicular helper T cell infiltration predicts breast cancer survival. J Clin Invest. 2013;123:2873–92. Article PubMed PMC
15. Lee HJ, Lee JJ, Song IH, Park IA, Kang J, Yu JH, et al. Prognostic and predictive value of NanoString-based immune-related gene signatures in a neoadjuvant setting of triple-negative breast cancer: relationship to tumor-infiltrating lymphocytes. Breast Cancer Res Treat. 2015;151:619–27. Article PubMed
16. Neyt K, Perros F, GeurtsvanKessel CH, Hammad H, Lambrecht BN. Tertiary lymphoid organs in infection and autoimmunity. Trends Immunol. 2012;33:297–305. Article PubMed PMC
17. Mahmoud SM, Paish EC, Powe DG, Macmillan RD, Grainge MJ, Lee AH, et al. Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer. J Clin Oncol. 2011;29:1949–55. Article PubMed
18. Liu S, Lachapelle J, Leung S, Gao D, Foulkes WD, Nielsen TO. CD8+ lymphocyte infiltration is an independent favorable prognostic indicator in basal-like breast cancer. Breast Cancer Res. 2012;14:R48.Article PubMed PMC
19. Schmidt M, Bohm D, von Torne C, Steiner E, Puhl A, Pilch H, et al. The humoral immune system has a key prognostic impact in node-negative breast cancer. Cancer Res. 2008;68:5405–13. Article PubMed
20. Brown JR, Wimberly H, Lannin DR, Nixon C, Rimm DL, Bossuyt V. Multiplexed quantitative analysis of CD3, CD8, and CD20 predicts response to neoadjuvant chemotherapy in breast cancer. Clin Cancer Res. 2014;20:5995–6005. Article PubMed PMC
21. Symmans WF, Peintinger F, Hatzis C, Rajan R, Kuerer H, Valero V, et al. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol. 2007;25:4414–22. Article PubMed
22. Salgado R, Denkert C, Demaria S, Sirtaine N, Klauschen F, Pruneri G, et al. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. Ann Oncol. 2015;26:259–71. Article PubMed
23. Geiss GK, Bumgarner RE, Birditt B, Dahl T, Dowidar N, Dunaway DL, et al. Direct multiplexed measurement of gene expression with color-coded probe pairs. Nat Biotechnol. 2008;26:317–25. Article PubMed
24. Bellone M, Calcinotto A. Ways to enhance lymphocyte trafficking into tumors and fitness of tumor infiltrating lymphocytes. Front Oncol. 2013;3:231.Article PubMed PMC
25. Mahmoud SM, Lee AH, Paish EC, Macmillan RD, Ellis IO, Green AR. The prognostic significance of B lymphocytes in invasive carcinoma of the breast. Breast Cancer Res Treat. 2012;132:545–53. Article PubMed
26. Seo AN, Lee HJ, Kim EJ, Kim HJ, Jang MH, Lee HE, et al. Tumour-infiltrating CD8+ lymphocytes as an independent predictive factor for pathological complete response to primary systemic therapy in breast cancer. Br J Cancer. 2013;109:2705–13. Article PubMed PMC
27. Kang H, Cheong H, Cho MS, Koo H, Han WS, Lee KE, et al. Significance of Foxp3 positive regulatory T cell and tumor infiltrating T lymphocyte in triple negative breast cancer. Korean J Pathol. 2011;45:53–61. Article
28. Nelson BH. CD20+ B cells: the other tumor-infiltrating lymphocytes. J Immunol. 2010;185:4977–82. Article PubMed

Figure & Data

REFERENCES

Citations

Citations to this article as recorded by

The discovery of high endothelial venules. A historical note
Domenico Ribatti
Translational Research in Anatomy.2025; 38: 100379. CrossRef
Immune microenvironment spatial landscapes of tertiary lymphoid structures in gastric cancer
Yi Xie, Haoxin Peng, Yajie Hu, Keren Jia, Jiajia Yuan, Dan Liu, Yanyan Li, Xujiao Feng, Jian Li, Xiaotian Zhang, Yu Sun, Lin Shen, Yang Chen
BMC Medicine.2025;[Epub] CrossRef
Bi-level graph learning unveils prognosis-relevant tumor microenvironment patterns in breast multiplexed digital pathology
Zhenzhen Wang, Cesar A. Santa-Maria, Aleksander S. Popel, Jeremias Sulam
Patterns.2025; 6(3): 101178. CrossRef
Multifaceted function of B cells in tumorigenesis
Na Kang, Qinghui Duan, Xin Min, Tong Li, Yuxin Li, Ji Gao, Wanli Liu
Frontiers of Medicine.2025; 19(2): 297. CrossRef
Prognostic significance of CD8 + tumor-infiltrating lymphocytes in operable breast cancer: a meta-analysis
Ruijie Niu, Cheng Wang, Yiqun Xie, Shuangshuang Li, Qian Zhao, Yuqing Chang, Zubing Mei
BMC Cancer.2025;[Epub] CrossRef
The tertiary lymphoid structure-related signature identified PTGDS in regulating PD-L1 and promoting the proliferation and migration of glioblastoma
Wantao Wu, He Li, Zeyu Wang, Ziyu Dai, Xisong Liang, Peng Luo, Kun Liu, Hao Zhang, Nan Zhang, Shuyu Li, Chi Zhang
Heliyon.2024; 10(1): e23915. CrossRef
Tertiary lymphoid structures, a historical reappraisal
Domenico Ribatti
Tissue and Cell.2024; 86: 102288. CrossRef
Immune cells within tertiary lymphoid structures are associated with progression‐free survival in patients with locoregional recurrent breast cancer
Jinyuan Gu, Jiaming Wang, Yue Sun, Xinrui Mao, Chao Qian, Xinyu Tang, Ji Wang, Hui Xie, Lijun Ling, Yi Zhao, Xiaoan Liu, Kai Zhang, Hong Pan, Shui Wang, Cong Wang, Wenbin Zhou
Cancer Medicine.2024;[Epub] CrossRef
Spatial Distribution of Immune Cells Drives Resistance to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer
Benedetta Donati, Francesca Reggiani, Federica Torricelli, Giacomo Santandrea, Teresa Rossi, Alessandra Bisagni, Elisa Gasparini, Antonino Neri, Laura Cortesi, Guglielmo Ferrari, Giancarlo Bisagni, Moira Ragazzi, Alessia Ciarrocchi
Cancer Immunology Research.2024; 12(1): 120. CrossRef
The Emerging Role of Tertiary Lymphoid Structures in Breast Cancer: A Narrative Review
Dana Narvaez, Jorge Nadal, Adrian Nervo, María Victoria Costanzo, Claudio Paletta, Fernando E. Petracci, Sergio Rivero, Alexis Ostinelli, Berenice Freile, Diego Enrico, Maria Teresa Pombo, Mora Amat, Edgar Danilo Aguirre, Matias Chacon, Federico Waisberg
Cancers.2024; 16(2): 396. CrossRef
Digital image analysis and machine learning-assisted prediction of neoadjuvant chemotherapy response in triple-negative breast cancer
Timothy B. Fisher, Geetanjali Saini, T. S. Rekha, Jayashree Krishnamurthy, Shristi Bhattarai, Grace Callagy, Mark Webber, Emiel A. M. Janssen, Jun Kong, Ritu Aneja
Breast Cancer Research.2024;[Epub] CrossRef
Translational and oncologic significance of tertiary lymphoid structures in pancreatic adenocarcinoma
Zachary Gao, Joseph Azar, Huili Zhu, Sophia Williams-Perez, Sung Wook Kang, Celia Marginean, Mark P. Rubinstein, Shalini Makawita, Hyun-Sung Lee, E. Ramsay Camp
Frontiers in Immunology.2024;[Epub] CrossRef
Tertiary lymphoid structures predict survival and response to neoadjuvant therapy in locally advanced rectal cancer
Qianyu Wang, Wentao Zhong, Xiaofei Shen, Zechen Hao, Meng Wan, Xiaopeng Yang, Ran An, Hongyan Zhu, Huiyun Cai, Tao Li, Yuan Lv, Xing Dong, Gang Chen, Aijun Liu, Junfeng Du
npj Precision Oncology.2024;[Epub] CrossRef
Advances in the study of tertiary lymphoid structures in the immunotherapy of breast cancer
Xin Li, Han Xu, Ziwei Du, Qiang Cao, Xiaofei Liu
Frontiers in Oncology.2024;[Epub] CrossRef
Macrophages and tertiary lymphoid structures as indicators of prognosis and therapeutic response in cancer patients
Li Niu, Ting Chen, Aodan Yang, Xiwen Yan, Feng Jin, Ang Zheng, Xinyue Song
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer.2024; 1879(5): 189125. CrossRef
Peripheral Blood CD8+ T-Lymphocyte Immune Response in Benign and Subpopulations of Breast Cancer Patients
Marek Lenárt, Peter Bober, Miroslav Marcin, Soňa Tkáčiková, Mária Kacírová, Michal Alexovič, Dávid Tóth, Natália Madárová, Jozef Radoňak, Peter Urdzík, Ján Fedačko, Ján Sabo
International Journal of Molecular Sciences.2024; 25(12): 6423. CrossRef
Integrated analysis of multiple transcriptomic approaches and machine learning integration algorithms reveals high endothelial venules as a prognostic immune-related biomarker in bladder cancer
Jinge Zhang, Yuan Huang, Xing Tan, Zihuan Wang, Ranyang Cheng, Shenlan Zhang, Yuwen Chen, Feifan Jiang, Wanlong Tan, Xiaolin Deng, Fei Li
International Immunopharmacology.2024; 136: 112184. CrossRef
Intratumoral high endothelial venules in solid tumors: a pooled study
Bin Wang, Yin Han, Jie Liu, Xinyao Zhang, Yaotiao Deng, Yu Jiang
Frontiers in Immunology.2024;[Epub] CrossRef
B‐cell performance in chemotherapy: Unravelling the mystery of B‐cell therapeutic potential
Zizhuo Li, Anqi Lin, Zhifei Gao, Aimin Jiang, Minying Xiong, Jiapeng Song, Zaoqu Liu, Quan Cheng, Jian Zhang, Peng Luo
Clinical and Translational Medicine.2024;[Epub] CrossRef
Density of tertiary lymphoid structures predicts clinical outcome in breast cancer brain metastasis
Yuan-Yuan Zhao, Zhen Fan, Bao-Rui Tao, Zun-Guo Du, Zhi-Feng Shi
Journal for ImmunoTherapy of Cancer.2024; 12(7): e009232. CrossRef
Tertiary lymphoid structures as potential biomarkers for cancer prediction and prognosis
Xin Zhang, Jie Yao, Mei Xie, Yiran Liang, Xuwen Lin, Jialin Song, Xinyu Bao, Xidong Ma, Yuanyong Wang, Yinguang Zhang, Yiming Liu, Wenya Han, Lei Pan, Xinying Xue
International Immunopharmacology.2024; 140: 112790. CrossRef
Tumor-Infiltrating Lymphocyte Scoring in Neoadjuvant-Treated Breast Cancer
Noémie Thomas, Soizic Garaud, Mireille Langouo, Doïna Sofronii, Anaïs Boisson, Alexandre De Wind, Valérie Duwel, Ligia Craciun, Dennis Larsimont, Ahmad Awada, Karen Willard-Gallo
Cancers.2024; 16(16): 2895. CrossRef
Co-expression network and survival analysis of breast cancer inflammation and immune system hallmark genes
Ayaka Yakushi, Masahiro Sugimoto, Takanori Sasaki
Computational Biology and Chemistry.2024; 113: 108204. CrossRef
Global trends in tertiary lymphoid structures: a bibliometric analysis from 2014 to 2023
Yiwen Bao, Zeming Mo, Shuang Wang, Jinhua Long, Honghong Zhang, Yujun Xu, Honglian Jiang, Tianbao Qian, Zhu Zeng
Frontiers in Immunology.2024;[Epub] CrossRef
Prognostic value of tertiary lymphoid structures in triple-negative breast cancer: integrated analysis with the tumor microenvironment and clinicopathological features
Florence Boissière-Michot, Marie-Christine Chateau, Simon Thézenas, Virginie Lafont, Evelyne Crapez, Priyanka Sharma, Angélique Bobrie, Pascal Roger, Séverine Guiu, William Jacot
Frontiers in Immunology.2024;[Epub] CrossRef
Prognostic value of tumor-infiltrating lymphocyte subtypes and microorganisms in triple-negative breast cancer
Yating Shi, Zhi Guo, Qiang Wang, Huan Deng
Journal of Cancer Research and Therapeutics.2024; 20(7): 1983. CrossRef
The prognostic impact of tumor-infiltrating B lymphocytes in patients with solid malignancies: A systematic review and meta-analysis
Hao Liu, Zhuoqun Li, Xuan Han, Zhujun Li, Yan Zhao, Fenghua Liu, Ziyu Zhu, Yi Lv, Zhijun Liu, Nana Zhang
Critical Reviews in Oncology/Hematology.2023; 181: 103893. CrossRef
Tertiary lymphoid structures in breast ductal carcinoma in situ correlate with adverse pathological parameters
Lixia Zeng, Valerie Cui Yun Koh, Xiao‐Yang Chen, Puay Hoon Tan
Histopathology.2023; 82(5): 779. CrossRef
Can CXCL13 be a prognostic marker in clear cell renal cell carcinoma?
Esma Sayar, Ayşegül Yabacı, Ganime Coban
Indian Journal of Pathology and Microbiology.2023; 66(1): 54. CrossRef
Clinical Significance of Tumour-Infiltrating B Lymphocytes (TIL-Bs) in Breast Cancer: A Systematic Literature Review
Brian M. Lam, Clare Verrill
Cancers.2023; 15(4): 1164. CrossRef
B cell‐dependent subtypes and treatment‐based immune correlates to survival in stage 3 and 4 lung adenocarcinomas
Susan Raju Paul, Ivan Valiev, Skylar E. Korek, Vladimir Zyrin, Diana Shamsutdinova, Olga Gancharova, Alexander Zaitsev, Ekaterina Nuzhdina, Diane L. Davies, Ibiayi Dagogo‐Jack, Felix Frenkel, Jessica H. Brown, Joshua M. Hess, Sarah Viet, Jason L. Petersen
FASEB BioAdvances.2023; 5(4): 156. CrossRef
High endothelial venules in cancer: Regulation, function, and therapeutic implication
Gerlanda Vella, Yichao Hua, Gabriele Bergers
Cancer Cell.2023; 41(3): 527. CrossRef
B Cells in Breast Cancer Pathology
Mengyuan Li, Angela Quintana, Elena Alberts, Miu Shing Hung, Victoire Boulat, Mercè Martí Ripoll, Anita Grigoriadis
Cancers.2023; 15(5): 1517. CrossRef
Therapeutic Potential of Tumor Metabolic Reprogramming in Triple-Negative Breast Cancer
Gyöngyi Munkácsy, Libero Santarpia, Balázs Győrffy
International Journal of Molecular Sciences.2023; 24(8): 6945. CrossRef
Antibodies against endogenous retroviruses promote lung cancer immunotherapy
Kevin W. Ng, Jesse Boumelha, Katey S. S. Enfield, Jorge Almagro, Hongui Cha, Oriol Pich, Takahiro Karasaki, David A. Moore, Roberto Salgado, Monica Sivakumar, George Young, Miriam Molina-Arcas, Sophie de Carné Trécesson, Panayiotis Anastasiou, Annika Fend
Nature.2023; 616(7957): 563. CrossRef
Predictive power of tertiary lymphoid structure signature for neoadjuvant chemotherapy response and immunotherapy benefit in HER2‐negative breast cancer
François Bertucci, Alexandre De Nonneville, Pascal Finetti, Emilie Mamessier
Cancer Communications.2023; 43(8): 943. CrossRef
P16 expression and presence of lymphoid stroma are correlated with good prognosis in mucoepidermoid carcinoma of the head and neck
Yeseul Kim, Joon Seon Song, Seung-Ho Choi, Soon Yuhl Nam, Sang Yoon Kim, Kyung-Ja Cho
Pathology - Research and Practice.2023; 251: 154874. CrossRef
The Possible Role of Anti- and Protumor-Infiltrating Lymphocytes in Pathologic Complete Response in Early Breast Cancer Patients Treated with Neoadjuvant Systemic Therapy
Klara Geršak, Blaž Matija Geršak, Barbara Gazić, Andreja Klevišar Ivančič, Primož Drev, Nina Ružić Gorenjec, Cvetka Grašič Kuhar
Cancers.2023; 15(19): 4794. CrossRef
Detection and quantitative analysis of tumor-associated tertiary lymphoid structures
Man Yang, Yurou Che, Kezhen Li, Zengyi Fang, Simin Li, Mei Wang, Yiyao Zhang, Zhu Xu, Liping Luo, Chuan Wu, Xin Lai, Weidong Wang
Journal of Zhejiang University-SCIENCE B.2023; 24(9): 779. CrossRef
Identification of an exosome-related signature associated with prognosis and immune infiltration in breast cancer
Qiaonan Guo, Kelun Pan, Pengjun Qiu, Zundong Liu, Jianpeng Chen, Jianqing Lin
Scientific Reports.2023;[Epub] CrossRef
Association of systemic inflammatory markers and tertiary lymphoid structure with pathological complete response in gastric cancer patients receiving preoperative treatment: a retrospective cohort study
Yingying Wu, Junjie Zhao, Zhaoming Wang, Dan Liu, Chenyu Tian, Botian Ye, Yihong Sun, Haojie Li, Xuefei Wang
International Journal of Surgery.2023; 109(12): 4151. CrossRef
The Characteristics of Tumor Microenvironment in Triple Negative Breast Cancer
Yiqi Fan, Shuai He
Cancer Management and Research.2022; Volume 14: 1. CrossRef
Peripheral node addressin, a ligand for L-selectin is found in tumor cells and in high endothelial venules in endometrial cancer
Georgia Karpathiou, Viviana Sramek, Sami Dagher, Mousa Mobarki, Maroa Dridi, Tiphanie Picot, Celine Chauleur, Michel Peoc’h
Pathology - Research and Practice.2022; 233: 153888. CrossRef
The Presence of Tertiary Lymphoid Structures Provides New Insight Into the Clinicopathological Features and Prognosis of Patients With Breast Cancer
Bin Wang, Jie Liu, Yin Han, Yaotiao Deng, Jinze Li, Yu Jiang
Frontiers in Immunology.2022;[Epub] CrossRef
Role of tertiary lymphoid organs in the regulation of immune responses in the periphery
Amit I. Bery, Hailey M. Shepherd, Wenjun Li, Alexander S. Krupnick, Andrew E. Gelman, Daniel Kreisel
Cellular and Molecular Life Sciences.2022;[Epub] CrossRef
Tertiary Lymphoid Structures as Mediators of Immunotherapy Response
Raj G. Vaghjiani, Joseph J. Skitzki
Cancers.2022; 14(15): 3748. CrossRef
Immunotherapy in triple-negative breast cancer: Insights into tumor immune landscape and therapeutic opportunities
Rita Ribeiro, Maria João Carvalho, João Goncalves, João Nuno Moreira
Frontiers in Molecular Biosciences.2022;[Epub] CrossRef
Predictive and prognostic values of tumor infiltrating lymphocytes in breast cancers treated with neoadjuvant chemotherapy: A meta-analysis
Shiqi Li, Ying Zhang, Peigen Zhang, Shuijing Xue, Yu Chen, Lihua Sun, Rui Yang
The Breast.2022; 66: 97. CrossRef
Multiplexed In Situ Spatial Protein Profiling in the Pursuit of Precision Immuno-Oncology for Patients with Breast Cancer
Davide Massa, Anna Tosi, Antonio Rosato, Valentina Guarneri, Maria Vittoria Dieci
Cancers.2022; 14(19): 4885. CrossRef
The Association of Estrogen Receptor Activity, Interferon Signaling, and MHC Class I Expression in Breast Cancer
In Hye Song, Young-Ae Kim, Sun-Hee Heo, Won Seon Bang, Hye Seon Park, Yeon ho Choi, Heejae Lee, Jeong-Han Seo, Youngjin Cho, Sung Wook Jung, Hee Jeong Kim, Sei Hyun Ahn, Hee Jin Lee, Gyungyub Gong
Cancer Research and Treatment.2022; 54(4): 1111. CrossRef
High endothelial venules associated with better prognosis in esophageal squamous cell carcinoma
Hongmu Li, Lu Tang, Xue Han, Leqi Zhong, Wuyou Gao, Youfang Chen, Jinhua Huang, Zhesheng Wen
Annals of Diagnostic Pathology.2022; 61: 152051. CrossRef
Tertiary lymphoid structures as unique constructions associated with the organization, education, and function of tumor-infiltrating immunocytes
Jing Chen, Jian Chen, Lie Wang
Journal of Zhejiang University-SCIENCE B.2022; 23(10): 812. CrossRef
Tertiary Lymphoid Structures: A Potential Biomarker for Anti-Cancer Therapy
Ji’an Zou, Yingzhe Zhang, Yue Zeng, Yurong Peng, Junqi Liu, Chaoyue Xiao, Fang Wu
Cancers.2022; 14(23): 5968. CrossRef
Impact of mature tertiary lymphoid structures on prognosis and therapeutic response of Epstein-Barr virus-associated gastric cancer patients
Yi-Xin Yin, Yi-Hong Ling, Xiao-Li Wei, Cai-Yun He, Bing-Zhi Wang, Chun-Fang Hu, Wen-Ping Lin, Run-Cong Nie, Jie-Wei Chen, Jin-Long Lin, Jie Zhou, Juan-Juan Xie, Jing-Ping Yun, Dan Xie, Li-Yan Xue, Mu-Yan Cai
Frontiers in Immunology.2022;[Epub] CrossRef
The Role of Immune Cells in Breast Tissue and Immunotherapy for the Treatment of Breast Cancer
Stephanie L. Goff, David N. Danforth
Clinical Breast Cancer.2021; 21(1): e63. CrossRef
Immune microenvironment in different molecular subtypes of ductal breast carcinoma
Mona Sadeghalvad, Hamid-Reza Mohammadi-Motlagh, Nima Rezaei
Breast Cancer Research and Treatment.2021; 185(2): 261. CrossRef
Cancer-Associated Fibroblasts and T Cells: From Mechanisms to Outcomes
Alfie T Baker, Mohammed H Abuwarwar, Lylarath Poly, Simon Wilkins, Anne L Fletcher
The Journal of Immunology.2021; 206(2): 310. CrossRef
Repenser la place des lymphocytes B et des structures lymphoïdes tertiaires dans l’immunothérapie des cancers
Claire Germain, Hélène Kaplon, Marie-Caroline Dieu-Nosjean
médecine/sciences.2021; 37(2): 130. CrossRef
High endothelial venules are present in pharyngeal and laryngeal carcinomas and they are associated with better prognosis
Georgia Karpathiou, Jean Marc Dumollard, Marie Gavid, Francois Casteillo, Marine Vieville, Jean Michel Prades, Marios Froudarakis, Michel Peoc’h
Pathology - Research and Practice.2021; 220: 153392. CrossRef
Prognostic value of tumor-infiltrating B lymphocytes and plasma cells in triple-negative breast cancer
Hajime Kuroda, Tsengelmaa Jamiyan, Rin Yamaguchi, Akinari Kakumoto, Akihito Abe, Oi Harada, Bayarmaa Enkhbat, Atsuko Masunaga
Breast Cancer.2021; 28(4): 904. CrossRef
Tumor-infiltrating B cells and T cells correlate with postoperative prognosis in triple-negative carcinoma of the breast
Hajime Kuroda, Tsengelmaa Jamiyan, Rin Yamaguchi, Akinari Kakumoto, Akihito Abe, Oi Harada, Atsuko Masunaga
BMC Cancer.2021;[Epub] CrossRef
Tertiary lymphoid structures and B lymphocytes in cancer prognosis and response to immunotherapies
Jacquelot N, Tellier J, Nutt Sl, Belz Gt
OncoImmunology.2021;[Epub] CrossRef
High endothelial venules (HEVs) in immunity, inflammation and cancer
Lucas Blanchard, Jean-Philippe Girard
Angiogenesis.2021; 24(4): 719. CrossRef
Immunohistochemical analysis of L1 cell adhesion molecule and high endothelial venules in breast cancer brain metastasis
Georgia Karpathiou, Florian Camy, Jean Marc Dumollard, Michel Peoc’h
Pathology - Research and Practice.2021; 223: 153484. CrossRef
The Immunology of Hormone Receptor Positive Breast Cancer
Jonathan Goldberg, Ricardo G. Pastorello, Tuulia Vallius, Janae Davis, Yvonne Xiaoyong Cui, Judith Agudo, Adrienne G. Waks, Tanya Keenan, Sandra S. McAllister, Sara M. Tolaney, Elizabeth A. Mittendorf, Jennifer L. Guerriero
Frontiers in Immunology.2021;[Epub] CrossRef
Immune Crosstalk Between Lymph Nodes and Breast Carcinomas, With a Focus on B Cells
Elena Alberts, Isobelle Wall, Dinis Pedro Calado, Anita Grigoriadis
Frontiers in Molecular Biosciences.2021;[Epub] CrossRef
Tumor-Associated Tertiary Lymphoid Structures: From Basic and Clinical Knowledge to Therapeutic Manipulation
Charlotte Domblides, Juliette Rochefort, Clémence Riffard, Marylou Panouillot, Géraldine Lescaille, Jean-Luc Teillaud, Véronique Mateo, Marie-Caroline Dieu-Nosjean
Frontiers in Immunology.2021;[Epub] CrossRef
The 12-CK Score: Global Measurement of Tertiary Lymphoid Structures
Roger Li, Anders Berglund, Logan Zemp, Jasreman Dhillon, Ryan Putney, Youngchul Kim, Rohit K. Jain, G. Daniel Grass, José Conejo-Garcia, James J. Mulé
Frontiers in Immunology.2021;[Epub] CrossRef
Immune checkpoint blockade in triple negative breast cancer influenced by B cells through myeloid-derived suppressor cells
Alyssa Vito, Omar Salem, Nader El-Sayes, Ian P. MacFawn, Ana L. Portillo, Katy Milne, Danielle Harrington, Ali A. Ashkar, Yonghong Wan, Samuel T. Workenhe, Brad H. Nelson, Tullia C. Bruno, Karen L. Mossman
Communications Biology.2021;[Epub] CrossRef
Cancer Immunotherapies: From Efficacy to Resistance Mechanisms – Not Only Checkpoint Matters
Shuyue Wang, Kun Xie, Tengfei Liu
Frontiers in Immunology.2021;[Epub] CrossRef
High Endothelial Venules: A Vascular Perspective on Tertiary Lymphoid Structures in Cancer
Gerlanda Vella, Sophie Guelfi, Gabriele Bergers
Frontiers in Immunology.2021;[Epub] CrossRef
Tumor-Infiltrating B Lymphocyte Profiling Identifies IgG-Biased, Clonally Expanded Prognostic Phenotypes in Triple-Negative Breast Cancer
Robert J. Harris, Anthony Cheung, Joseph C.F. Ng, Roman Laddach, Alicia M. Chenoweth, Silvia Crescioli, Matthew Fittall, Diana Dominguez-Rodriguez, James Roberts, Dina Levi, Fangfang Liu, Elena Alberts, Jelmar Quist, Aida Santaolalla, Sarah E. Pinder, Che
Cancer Research.2021; 81(16): 4290. CrossRef
Tertiary lymphoid structure and B‑cell‑related pathways: A potential target in tumor immunotherapy (Review)
Meng Qin, Ying Jin, Ling-Ya Pan
Oncology Letters.2021;[Epub] CrossRef
Heterogeneity of Circulating Tumor Cell–Associated Genomic Gains in Breast Cancer and Its Association with the Host Immune Response
Nisha Kanwar, Zaldy Balde, Ranju Nair, Melanie Dawe, Shiyi Chen, Manjula Maganti, Eshetu G. Atenafu, Sabrina Manolescu, Carrie Wei, Amanda Mao, Fred Fu, Dan Wang, Alison Cheung, Yulia Yerofeyeva, Rachel Peters, Kela Liu, Christine Desmedt, Christos Sotiri
Cancer Research.2021; 81(24): 6196. CrossRef
Oral cancer-associated tertiary lymphoid structures: gene expression profile and prognostic value
K Li, Q Guo, X Zhang, X Dong, W Liu, A Zhang, Y Li, J Yan, G Jia, Z Zheng, W Tang, L Pan, M An, B Zhang, S Liu, B Fu
Clinical and Experimental Immunology.2020; 199(2): 172. CrossRef
B cells and tertiary lymphoid structures promote immunotherapy response
Beth A. Helmink, Sangeetha M. Reddy, Jianjun Gao, Shaojun Zhang, Rafet Basar, Rohit Thakur, Keren Yizhak, Moshe Sade-Feldman, Jorge Blando, Guangchun Han, Vancheswaran Gopalakrishnan, Yuanxin Xi, Hao Zhao, Rodabe N. Amaria, Hussein A. Tawbi, Alex P. Cogdi
Nature.2020; 577(7791): 549. CrossRef
Neolymphogenesis and Immunogistogochemical Study of Lymph Nodes in Breast Cancer
Sh. Kh. Gantsev, R. A. Rustamkhanov, Sh. R. Kzyrgalin, D. S. Tursumetov
Creative surgery and oncology.2020; 9(4): 266. CrossRef
Duality of B Cell-CXCL13 Axis in Tumor Immunology
Angel J. Rubio, Tyrone Porter, Xuemei Zhong
Frontiers in Immunology.2020;[Epub] CrossRef
Predictive and prognostic role of tumour-infiltrating lymphocytes in breast cancer patients with different molecular subtypes: a meta-analysis
Zhao-hua Gao, Cun-xin Li, Ming Liu, Jia-yuan Jiang
BMC Cancer.2020;[Epub] CrossRef
Insights into Tumor-Associated Tertiary Lymphoid Structures: Novel Targets for Antitumor Immunity and Cancer Immunotherapy
Anthony B. Rodriguez, Victor H. Engelhard
Cancer Immunology Research.2020; 8(11): 1338. CrossRef
Pan-cancer analysis of genomic properties and clinical outcome associated with tumor tertiary lymphoid structure
Ziying Lin, Lixia Huang, ShaoLi Li, Jincui Gu, Xiaoxian Cui, Yanbin Zhou
Scientific Reports.2020;[Epub] CrossRef
Presence of tertiary lymphoid structures determines the level of tumor-infiltrating lymphocytes in primary breast cancer and metastasis
Miseon Lee, Sun-Hee Heo, In Hye Song, Hajar Rajayi, Hye Seon Park, In Ah Park, Young-Ae Kim, Heejae Lee, Gyungyub Gong, Hee Jin Lee
Modern Pathology.2019; 32(1): 70. CrossRef
Strong CD8+ lymphocyte infiltration in combination with expression of HLA class I is associated with better tumor control in breast cancer patients treated with neoadjuvant chemotherapy
A. F. de Groot, E. J. Blok, A. Charehbili, C. C. Engels, V. T. H. B. M. Smit, N. G. Dekker-Ensink, H. Putter, E. Meershoek-Klein Kranenbarg, C. J. H. van de Velde, G. J. Liefers, J. W. R. Nortier, P. J. K. Kuppen, S. H. van der Burg, J. R. Kroep
Breast Cancer Research and Treatment.2019; 175(3): 605. CrossRef
The effect of C-X-C motif chemokine ligand 13 in cutaneous squamous cell carcinoma treated with aminolevulinic acid-photodynamic therapy
Lude Zhu, Guolong Zhang, Peiru Wang, Linglin Zhang, Jie Ji, Xiaojing Liu, Zhongxia Zhou, Jingjun Zhao, Xiuli Wang
Photodiagnosis and Photodynamic Therapy.2019; 26: 389. CrossRef
Tertiary lymphoid structures in the era of cancer immunotherapy
Catherine Sautès-Fridman, Florent Petitprez, Julien Calderaro, Wolf Herman Fridman
Nature Reviews Cancer.2019; 19(6): 307. CrossRef
B cells sustain inflammation and predict response to immune checkpoint blockade in human melanoma
Johannes Griss, Wolfgang Bauer, Christine Wagner, Martin Simon, Minyi Chen, Katharina Grabmeier-Pfistershammer, Margarita Maurer-Granofszky, Florian Roka, Thomas Penz, Christoph Bock, Gao Zhang, Meenhard Herlyn, Katharina Glatz, Heinz Läubli, Kirsten D. M
Nature Communications.2019;[Epub] CrossRef
Poor Response to Neoadjuvant Chemotherapy Correlates with Mast Cell Infiltration in Inflammatory Breast Cancer
Sangeetha M. Reddy, Alexandre Reuben, Souptik Barua, Hong Jiang, Shaojun Zhang, Linghua Wang, Vancheswaran Gopalakrishnan, Courtney W. Hudgens, Michael T. Tetzlaff, James M. Reuben, Takahiro Tsujikawa, Lisa M. Coussens, Khalida Wani, Yan He, Lily Villarea
Cancer Immunology Research.2019; 7(6): 1025. CrossRef
New Insights into Tumor-Infiltrating B Lymphocytes in Breast Cancer: Clinical Impacts and Regulatory Mechanisms
Meng Shen, Jian Wang, Xiubao Ren
Frontiers in Immunology.2018;[Epub] CrossRef
Hot Spot and Whole-Tumor Enumeration of CD8+ Tumor-Infiltrating Lymphocytes Utilizing Digital Image Analysis Is Prognostic in Triple-Negative Breast Cancer
Patrick J. McIntire, Lina Irshaid, Yifang Liu, Zhengming Chen, Faith Menken, Eugene Nowak, Sandra J. Shin, Paula S. Ginter
Clinical Breast Cancer.2018; 18(6): 451. CrossRef
Correlation with lymphocyte infiltration, but lack of prognostic significance of MECA-79-positive high endothelial venules in primary malignant melanoma
Tímea Sebestyén, Anita Mohos, Gabriella Liszkay, Beáta Somlai, István Gaudi, Andrea Ladányi
Melanoma Research.2018; 28(4): 304. CrossRef
Lymphocyte-Activation Gene-3 Expression and Prognostic Value in Neoadjuvant-Treated Triple-Negative Breast Cancer
Yunxuan Wang, Tieying Dong, Qijia Xuan, Hong Zhao, Ling Qin, Qingyuan Zhang
Journal of Breast Cancer.2018; 21(2): 124. CrossRef
Functions of the CXC ligand family in the pancreatic tumor microenvironment
Nien-Hung Lee, Mehrdad Nikfarjam, Hong He
Pancreatology.2018; 18(7): 705. CrossRef
Antigen Specificity and Clinical Significance of IgG and IgA Autoantibodies Produced in situ by Tumor-Infiltrating B Cells in Breast Cancer
Soizic Garaud, Pawel Zayakin, Laurence Buisseret, Undine Rulle, Karina Silina, Alexandre de Wind, Gert Van den Eyden, Denis Larsimont, Karen Willard-Gallo, Aija Linē
Frontiers in Immunology.2018;[Epub] CrossRef
Prognostic Significance of Tumor-Infiltrating B Cells and Plasma Cells in Human Cancer
Maartje C.A. Wouters, Brad H. Nelson
Clinical Cancer Research.2018; 24(24): 6125. CrossRef
The Multifaceted Roles of B Cells in Solid Tumors: Emerging Treatment Opportunities
Nicole J. Flynn, Rajasekharan Somasundaram, Kimberly M. Arnold, Jennifer Sims-Mourtada
Targeted Oncology.2017; 12(2): 139. CrossRef
CXCL13-producing TFH cells link immune suppression and adaptive memory in human breast cancer
Chunyan Gu-Trantien, Edoardo Migliori, Laurence Buisseret, Alexandre de Wind, Sylvain Brohée, Soizic Garaud, Grégory Noël, Luan Dang C.V., Jean-Nicolas Lodewyckx, Céline Naveaux, Hugues Duvillier, Stanislas Goriely, Denis Larsimont, Karen Willard-Gallo
JCI Insight.2017;[Epub] CrossRef
Tertiary Lymphoid Structures in Cancer: Drivers of Antitumor Immunity, Immunosuppression, or Bystander Sentinels in Disease?
Emily Jayne Colbeck, Ann Ager, Awen Gallimore, Gareth Wyn Jones
Frontiers in Immunology.2017;[Epub] CrossRef
Distinct Tertiary Lymphoid Structure Associations and Their Prognostic Relevance in HER2 Positive and Negative Breast Cancers
Xia Liu, Julia Y.S. Tsang, Thazin Hlaing, Jintao Hu, Yun-Bi Ni, Siu Ki Chan, Sai Yin Cheung, Gary M. Tse
The Oncologist.2017; 22(11): 1316. CrossRef

PubReader
ePub Link

Cite

CITE: export Copy Download Format; Close

Download Citation

Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

Format:

RIS — For EndNote, ProCite, RefWorks, and most other reference management software
BibTeX — For JabRef, BibDesk, and other BibTeX-specific software

Include:

Citation for the content below
Citation and abstract for the content below

Predictive Value of Tertiary Lymphoid Structures Assessed by High Endothelial Venule Counts in the Neoadjuvant Setting of Triple-Negative Breast Cancer

Cancer Res Treat. 2017;49(2):399-407. Published online July 27, 2016

DOI: https://doi.org/10.4143/crt.2016.215

XML Download

Abstract
Introduction
Materials and Methods
Results
Discussion
Conclusion
Electronic Supplementary Material
NOTES
REFERENCES

Predictive Value of Tertiary Lymphoid Structures Assessed by High Endothelial Venule Counts in the Neoadjuvant Setting of Triple-Negative Breast Cancer

Fig. 1. High endothelial venules (HEVs) in needle biopsy specimens of triple-negative breast cancer. (A) Representative microscopic images of HEVs immunohistochemically stained with MECA79 (×400). (B) Absolute number and density of HEVs in tumors (n=55).

Fig. 2. Representative microscopy images of tumor-infiltrating lymphocyte subpopulations in triple-negative breast cancer sections with immunohistochemical staining.

Fig. 1.

Fig. 2.

Predictive Value of Tertiary Lymphoid Structures Assessed by High Endothelial Venule Counts in the Neoadjuvant Setting of Triple-Negative Breast Cancer

Parameter	Tumors without available FFPE blocks (n=53)	Tumors with available FFPE blocks (n=55)	p-value
Age (yr)	43.9±10.2	41.4±9.6	0.181
Clinical tumor stage
T1	4 (7.5)	4 (7.3)	0.942
T2	27 (50.9)	31 (56.4)
T3	19 (35.8)	18 (32.7)
T4	3 (5.7)	2 (3.6)
Clinical nodal status
N0	5 (9.4)	1 (1.8)	0.331
N1	21 (39.6)	27 (49.1)
N2	12 (22.6)	11 (20.0)
N3	15 (28.3)	16 (29.1)
Histologic grade
2	24 (45.3)	25 (45.5)	1
3	29 (54.7)	30 (54.5)
TIL (%)	23.3±20.6	25.9±21.0	0.471
TLS
None	9 (22.5)	6 (13.0)	0.198
Mild	12 (30.0)	9 (19.6)
Moderate	14 (35.0)	18 (39.1)
Abundant	5 (12.5)	13 (28.3)
Germinal center in TLSs
Absent	36 (97.3)	44 (95.7)	1
Present	1 (2.7)	2 (4.3)
pCR
Absent	37 (69.8)	38 (69.1)	1
Present	16 (30.2)	17 (30.9)
Miller-Payne grade
Grade 1	1 (1.9)	0	0.115
Grade 2	2 (3.8)	10 (18.2)
Grade 3	18 (34.0)	14 (25.5)
Grade 4	12 (22.6)	13 (23.6)
Grade 5	20 (37.7)	18 (32.7)
RCB class
0	16 (30.2)	17 (30.9)	0.295
1	5 (9.4)	1 (1.8)
2	20 (37.7)	27 (49.1)
3	12 (22.6)	10 (18.2)

Parameter	Univariate analysis			Multivariate analysis
Parameter	HR	95% CI	p-value	HR	95% CI	p-value
Clinical tumor stage			0.067			0.304
T1
T2	0.150	0.028-0.816	0.028	0.294	0.046-1.862	0.193
T3	0.092	0.015-0.546	0.009	0.147	0.020-1.094	0.061
T4	0.083	0.006-1.257	0.073	0.289	0.015-5.418	0.406
Clinical nodal status			0.690			-
N0
N1	1.097	0.182-6.618	0.920	-	-	-
N2	0.875	0.129-5.943	0.891	-	-	-
N3	0.583	0.088-3.880	0.577	-	-	-
Histologic grade (3 vs. 2)	1.704	0.735-3.953	0.214	-	-	-
TIL in biopsies	1.025	1.005-1.046	0.016	1.038	1.012-1.065	0.004
TLS in biopsies			0.147			0.925
None
Little	2.031	0.337-12.24	0.439	1.086	0.158-7.472	0.933
Moderate	2.955	0.559-15.63	0.202	1.478	0.248-8.815	0.668
Abundant	6.500	1.127-37.48	0.036	1.721	0.213-13.92	0.611

Parameter	Univariate analysis			Multivariate analysis
Parameter	HR	95% CI	p-value	HR	95% CI	p-value
cT stage (T3-4 vs. T1-2)	2.335	1.252-4.355	0.008	1.877	0.923-3.813	0.082
cN stage (N2-3 vs. N0-1)	1.652	0.881-3.096	0.117	1.722	0.847-3.501	0.133
Histologic grade (3 vs. 2)	0.796	0.427-1.483	0.473
TIL in biopsies	0.975	0.957-0.993	0.007	0.975	0.954-0.997	0.028
TLS in biopsies (abundant vs. none to moderate)	0.327	0.100-1.074	0.065	0.624	0.164-2.374	0.489

Parameter	Predictive value for pCR			Disease-free survival
Parameter	HR	95% CI	p-value	HR	95% CI	p-value
HEV density	20.325	1.455-283.857	0.025	0.091	0.006-1.421	0.087
CD8-positive cell density	1.001	0.999-1.002	0.222	0.998	0.996-1.000	0.037
CD3-positive cell density	1.003	1.000-1.005	0.052	0.999	0.997-1.001	0.452
CD20-positive cell density	1.004	1.000-1.007	0.037	0.998	0.996-1.001	0.194
CXCL13 gene expression	1.706	1.079-2.696	0.022	0.634	0.478-0.841	0.002

Table 1. Clinicopathologic characteristics of the tumors according to the availability of FFPE tumor blocks

Table 2. Predictive values of TIL, TLS, and other clinicopathological parameters prior to neoadjuvant chemotherapy for a pathologic complete response in 108 cases

TIL, tumor-infiltrating lymphocytes; TLS, tertiary lymphoid structure; HR, hazard ratio; CI, confidence interval.

Table 3. Disease-free survival analyses based on TIL, TLS, and clinicopathological parameters in 108 cases

TIL, tumor-infiltrating lymphocytes; TLS, tertiary lymphoid structure; HR, hazard ratio; CI, confidence interval.

Table 4. Predictive value for pCR and the prognostic significance of the protein and gene expression of TIL-associated molecules and HEV density in cases with available FFPE tissue blocks

pCR, pathologic complete response; TIL, tumor-infiltrating lymphocyte; HEV, high endothelial venule; FFPE, formalin-fixed paraffin-embedded; HR, hazard ratio; CI, confidence interval.